贝达药业盐酸恩沙替尼胶囊在美国开出首张处方单

Core Viewpoint - The announcement highlights the successful prescription of a new innovative drug, Ensartinib, by Betta Pharmaceuticals and its subsidiary Xcovery Holdings, marking a significant milestone in the development of targeted therapies for lung cancer [1] Company Summary - Betta Pharmaceuticals has developed Ensartinib (brand name: Baimena), a novel and highly selective next-generation ALK inhibitor [1] - The drug has received FDA approval for market entry in December 2024, making it the first small molecule targeted innovative drug led by a Chinese company to be launched globally [1] Industry Summary - Ensartinib represents a significant advancement in the field of targeted cancer therapies, particularly for lung cancer, which is a major area of focus in oncology [1] - The successful prescription at the Martin O'Neill Cancer Center in California indicates the drug's entry into the competitive U.S. market, potentially enhancing the company's position in the global pharmaceutical landscape [1]